Dietlein Lab

Our lab aims to decode the key principles of cancer genomics in tumor development and use them as an “Achilles heel” for targeted cancer therapies. We are a diverse group of scientists with a common research interest in cancer genomics, tumor biology, and targeted therapies. We combine statistics, machine learning, tumor biology, and functional genomics for a data-driven understanding of the molecular architecture of tumor genomes and the development of genome-inspired therapies. We are committed to training a new generation of cancer researchers from computational, experimental, and clinical backgrounds who share our core values of teaching and mentorship, collegiality and collaboration, inclusion and diversity, and mutual respect and open communication.

Cava Lab

We are a multi-disciplinary group, open to students in clinical and biomedical sciences, computer science, statistics, engineering, and related fields. We seek clarity and fairness from complex problems that necessitate interdisciplinary approaches. Our goals are to cultivate an environment for critical thinking, research creativity and open scientific collaboration. In addition, this lab is a good fit for those who wish to gain expertise in biomedical informatics and machine learning, especially when interpretability and fairness are central concerns.

Natural Language Processing Laboratory

Our mission is to develop and implement Natural Language Processing (NLP) technologies to apply to the electronic medical record.  These technologies include core NLP tasks such as relation extraction, coreference resolution, and parsing, and make use of statistical machine learning methods.  In order to use many machine learning methods, manually labeled (annotated) domain- and task-specific data is required.  To that end, we are heavily involved in many different clinical document annotation projects.  Since manual annotation is a time-consuming, painstaking, expensive process, it is also our goal to develop and use algorithms that minimize the required amount of labeled data required while maximizing the use of existing labeled data.

The Programmatic Outbreak Response and [socio-]Technical Analytics Lab (PORTAL)

PORTAL uses probabilistic modeling, data science, and “systems epidemiology” in the context of public health, with a focus on causal inference to advance infectious disease surveillance using digital disease data (e.g. search trends; news and social media).

The Registry and Informatics R&D (RIR&D) Group

The RIR&D Group is focused on the development and application of innovative, open-source, data-driven solutions to challenges faced by longitudinal disease registries and related studies. A principal focus of our group is informatics-based strategies to enhance the collection and sharing of clinical research data within the 75+ site Childhood Arthritis and Rheumatology Research Alliance (CARRA) Registry, serving as a paradigm for other similar longitudinal chronic disease registries. Members of the CHIP RIR&D Group include specialists in software architecture and development for multi-site/multi-source regulatory-grade clinical research data warehousing, research data coordination, research analytics and computable phenotyping, and related IRB and regulatory/legal matters for clinical trials.

The Manrai Lab

The Manrai Lab is a team of machine learning scientists, clinicians, and biomedical data scientists working to improve medical decision making by developing computational approaches that incorporate rich and deep representations of clinical state and an individual's identity into care. Active projects include: improving genetic variant classification and quantifying risk ("penetrance") for inherited heart disease, measuring "normal" variation for blood lab biomarkers across populations focused on creatinine and kidney disease, developing semi-supervised learning approaches for multi-modal imaging, and modeling reproducibility in integrative biomedical studies using meta-science ("science of science") approaches.

The Pediatric Therapeutics and Regulatory Science Initiative

The Pediatric Therapeutics and Regulatory Science Initiative provides a forum for collaboration with academia, patients, policymakers, and industry. Its aim is to advance the development and evidence-based use of novel therapeutics for children globally.

Inclusion Body Myositis Research

The Inclusion Body Myositis Research group is dedicated to understanding and finding treatment for sporadic inclusion body myositis (s-IBM), dermatomyositis, polymyositis, and other inflammatory myopathies.


SMART Health IT advances medicine, discovery and public health through parsimonious, open standards, application programming interfaces, laws and regulation, and is best known for the SMART on FHIR API. 

Laboratory for Neuroinformatics and Neurodiagnostics (LNN)

The LNN develops computational methods for extracting digital biomarkers for brain disorders from EEG measurements. Our approach to EEG signal analysis is based in complex dynamical systems theory. Entropy measures, recurrence plot and recurrence network analysis, neural synchronization, and tensor data structures all play a role. 

Computational Epidemiology Lab

The Computational Epidemiology Lab conducts a diverse set of projects to predict patterns of disease, analyze patterns of epidemics, use of satellite data and public health surveillance tools. 

Avillach Lab

The Avillach Lab investigates translational bioinformatics, specifically in integrating multiple heterogeneous sources of clinical and genomics data in a meaningful way. 

Translational Omics Medicine Lab

The Translational Omics Medicine Lab develops methods to molecularly characterize patients for research and discovery. 

Machine Intelligence Lab

The Machine Intelligence Lab has a multidisciplinary research agenda. The research involves the conception and implementation of machine intelligence analytics tools, capable of predicting unobserved events in health care in the immediate or near future. 

Predictive Medicine Group

The Predictive Medicine Group works to develop novel approaches for predicting human health. Our diverse group of researchers, clinicians, mathematicians, computer scientists and biologists develop advanced predictive models for a wide range of applicants, including disease risk prediction, predictive pharmacovigilance, predictive health system dynamics and real-time public health surveillance. 


Hopper RK, Abman SH, Elia EG, Avitabile CM, Yung D, Mullen MP, Austin ED, Bates A, Handler SS, Feinstein JA, Ivy DD, Kinsella JP, Mandl KD, Raj JU, Sleeper LA, . Pulmonary Hypertension in Children with Down Syndrome: Results from the Pediatric Pulmonary Hypertension Network Registry. The Journal of pediatrics 2022.

Wang X, Zhang HG, Xiong X, Hong C, Weber GM, Brat GA, Bonzel CL, Luo Y, Duan R, Palmer NP, Hutch MR, Gutiérrez-Sacristán A, Bellazzi R, Chiovato L, Cho K, Dagliati A, Estiri H, García-Barrio N, Griffier R, Hanauer DA, Ho YL, Holmes JH, Keller MS, Klann MEng JG, L'Yi S, Lozano-Zahonero S, Maidlow SE, Makoudjou A, Malovini A, Moal B, Moore JH, Morris M, Mowery DL, Murphy SN, Neuraz A, Yuan Ngiam K, Omenn GS, Patel LP, Pedrera-Jiménez M, Prunotto A, Jebathilagam Samayamuthu M, Sanz Vidorreta FJ, Schriver ER, Schubert P, Serrano-Balazote P, South AM, Tan ALM, Tan BWL, Tibollo V, Tippmann P, Visweswaran S, Xia Z, Yuan W, Zöller D, Kohane IS, Avillach P, Guo Z, Cai T, . SurvMaximin: Robust federated approach to transporting survival risk prediction models. Journal of biomedical informatics 2022.

Torous J, Stern AD, Bourgeois FT. Regulatory considerations to keep pace with innovation in digital health products. NPJ digital medicine 2022.

Levy S, Wisk LE, Minegishi M, Ertman B, Lunstead J, Brogna M, Weitzman ER. Association of Screening and Brief Intervention With Substance Use in Massachusetts Middle and High Schools. JAMA network open 2022.

Nielsen M, Presti M, Sztupinszki Z, Jensen AWP, Draghi A, Chamberlain CA, Schina A, Yde CW, Wojcik J, Szallasi Z, Crowther MD, Svane IM, Donia M. Co-existing alterations of MHC class I antigen presentation and IFNγ signaling mediate acquired resistance of melanoma to post-PD-1 immunotherapy. Cancer immunology research 2022.